Anticoagulation Management for Budd-Chiari Syndrome in Pediatric Patients

Initial Anticoagulation Strategy

The European Association for the Study of the Liver (EASL) recommends that children with Budd-Chiari syndrome and cirrhosis should receive immediate and indefinite anticoagulation with low molecular weight heparin (LMWH) followed by vitamin K antagonist (VKA) therapy, targeting an INR of 2-3, regardless of the presence of portal hypertension 1
LMWH should be started immediately upon diagnosis for at least 5-7 days while simultaneously initiating oral VKA therapy, and can be discontinued once INR reaches therapeutic range (2-3) for two consecutive measurements 1
Anticoagulation should be initiated as soon as possible to prevent clot extension and new thrombotic episodes, and should be continued indefinitely as this is a lifelong requirement for Budd-Chiari syndrome 1

Before initiating anticoagulation, screening for esophageal varices using upper endoscopy is necessary, and adequate prophylaxis for portal hypertension-related bleeding should be in place 1, 2
Appropriate variceal management (beta-blockers or endoscopic band ligation) should be implemented if varices are present, as bleeding complications historically occurred in up to 50% of patients when portal hypertension was inadequately managed, though more recent data shows only 17% bleeding rates with proper prophylaxis 1, 2

The preferred regimen for children with cirrhosis is LMWH bridging to VKA (warfarin) as the standard approach, as recommended by the EASL guidelines 1
Direct oral anticoagulants (DOACs) are not recommended in pediatric populations due to lack of safety and efficacy data in children 3

Anticoagulation should not be withheld for platelet counts >50 × 10⁹/L, but for platelet counts 25-50 × 10⁹/L, consideration of dose reduction based on thrombus burden may be necessary 4
For platelet counts <25 × 10⁹/L, evaluation of risk of thrombus extension versus bleeding risk, considering platelet transfusion support during initial treatment period, is recommended 4

The underlying prothrombotic disorder should be investigated and addressed simultaneously, including myeloproliferative neoplasms, inherited thrombophilias, or other hypercoagulable states, as early treatment of underlying conditions improves outcomes 1
Portal hypertension complications, such as ascites and varices, should be managed following standard cirrhosis management guidelines, and consideration of TIPS or liver transplantation may be necessary if medical therapy with anticoagulation fails 1, 5, 6, 7

INR should be monitored closely, targeting 2-3 throughout treatment, and Doppler ultrasound should be performed early after treatment initiation, then every 6 months to assess hepatic vein patency 1, 7

Failing to screen for and treat varices before anticoagulation, excessive anticoagulation (INR >3), inadequate monitoring during invasive procedures, and interrupting anticoagulation prematurely are common errors that increase bleeding risk 1, 2
Most major bleeding is related to invasive procedures for BCS treatment, and presence of esophageal varices is the strongest independent predictor of spontaneous bleeding 1, 2

If anticoagulation alone fails, consideration of angioplasty with stenting, TIPS, or liver transplantation may be necessary, and all children with Budd-Chiari syndrome should be managed at centers with expertise in vascular liver diseases and access to liver transplantation 1, 5, 6, 7